Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.08)
# 4,315
Out of 4,945 analysts
4
Total ratings
25%
Success rate
-40.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $24.96 | +264.58% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $1.07 | +1,021.50% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $82.71 | +35.41% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $24.96
Upside: +264.58%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.07
Upside: +1,021.50%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $82.71
Upside: +35.41%